Sanofi launches high-capacity insulin glargine pen to optimize long-acting treatment experience

In 2018, the FDA approved Toujeo MAX SoloStar from Sanofi, marking the first high-capacity long-acting insulin pen with 900 units on the US market. This device supports single injections of up to 160 units/ml of insulin, significantly reducing the injection frequency for patients requiring large doses.
Its design not only enhances medication convenience but also reduces the treatment burden by decreasing the frequency of injections, making it particularly suitable for patients with type 2 diabetes who exhibit strong insulin resistance.